Cullen Frost Bankers Inc. Boosts Holdings in Cencora, Inc. (NYSE:COR)

Cullen Frost Bankers Inc. raised its holdings in Cencora, Inc. (NYSE:COR) by 1.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 4,463 shares of the company’s stock after acquiring an additional 47 shares during the period. Cullen Frost Bankers Inc.’s holdings in Cencora were worth $1,003,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the business. Verdence Capital Advisors LLC boosted its holdings in Cencora by 1.6% in the fourth quarter. Verdence Capital Advisors LLC now owns 28,636 shares of the company’s stock valued at $6,434,000 after purchasing an additional 453 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Cencora in the fourth quarter valued at $31,936,000. M&T Bank Corp boosted its holdings in Cencora by 4.3% in the fourth quarter. M&T Bank Corp now owns 15,592 shares of the company’s stock valued at $3,503,000 after purchasing an additional 636 shares during the last quarter. Assetmark Inc. boosted its holdings in Cencora by 1,165.7% in the fourth quarter. Assetmark Inc. now owns 32,097 shares of the company’s stock valued at $7,212,000 after purchasing an additional 29,561 shares during the last quarter. Finally, Triad Wealth Partners LLC purchased a new stake in Cencora in the fourth quarter valued at $463,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,648 shares of company stock worth $2,862,342. Insiders own 10.80% of the company’s stock.

Cencora Stock Up 0.3 %

COR opened at $254.54 on Friday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a 50-day moving average price of $244.34 and a 200 day moving average price of $238.40. The company has a market cap of $49.36 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. Cencora’s payout ratio is 31.29%.

Analyst Ratings Changes

Several research firms have recently issued reports on COR. Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. StockNews.com lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Tuesday. Wells Fargo & Company increased their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.